Metabolic Disease Program
Type 1 Diabetes
Key Facts
About Kriya Therapeutics
Kriya Therapeutics is a well-funded, clinical-stage gene therapy company targeting large-market, chronic diseases in ophthalmology, metabolic disorders, and neurology. The company has raised over $900 million, including a $320 million Series D in late 2025, to advance its pipeline and internal manufacturing platform. Led by an experienced team with recent key C-suite appointments, Kriya aims to redefine gene therapy by addressing conditions with high unmet need that impact millions of patients.
View full company profileAbout Kriya Therapeutics
Kriya Therapeutics is a well-funded, clinical-stage gene therapy company targeting large-market, chronic diseases in ophthalmology, metabolic disorders, and neurology. The company has raised over $900 million, including a $320 million Series D in late 2025, to advance its pipeline and internal manufacturing platform. Led by an experienced team with recent key C-suite appointments, Kriya aims to redefine gene therapy by addressing conditions with high unmet need that impact millions of patients.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |